



**To:** UCM Hyde Park Medical Staff, House Staff, Nursing, and Pharmacy

**From:** Krzysztof Mikrut, B.S, MT (ASCP)  
Technical Director, Coagulation Laboratory

Geoffrey Wool, M.D., Ph.D.  
Medical Director, Coagulation Laboratory

**Date:** 3/4/2024


**Subject:** Change of aPTT heparin therapeutic range

**Effective Date:** 3/4/2024

**Laboratory Section:** Coagulation

1. The Coagulation Laboratory must reassess reference and therapeutic intervals for the activated PTT (aPTT) with the switch to new reagent lots. This reagent lot change will take place at 03/04/24 at 00:01. Normal range for the new lot of aPTT reagent is unchanged at 25-34 seconds.
2. **The heparin therapeutic range will change.**  
**New relationships between aPTT and anti-Xa levels:**

Anti-Xa (U/mL)	aPTT (sec)
0.3	73
0.7	101
<i>Additional relationships will be provided in the aPTT result comment and were made available to Pharmacy for nomogram updates</i>	



*As the above graph shows, any individual heparinized patient might not closely adhere to the population's linear regression relationship between aPTT and anti-Xa activity and could therefore potentially benefit from anti-Xa based heparin monitoring.*

We recommend referring to UCM Policy PGP-23 (Adult Continuous Infusion Unfractionated Heparin (UFH)), for the details of heparin dosing and monitoring recommendations from UCM Pharmacy.

**Questions:** Please contact Krzysztof Mikrut, Laboratory Manager, at 773-702-1315, or Geoffrey Wool, MD PhD, Medical Director, at 773-926-1455.

